For more information, follow the links below to view each study's clinical trial fact sheet and study listing on clinicaltrials.gov. Medical professionals may also email us at clinicaltrials@deciphera.com for specific questions related to our clinical studies.

Oncology

QINLOCK®

(Ripretinib)
ª
KIT inhibitor
  • Advanced GIST after 3 TKIs ᵇ
  • 2L GIST KIT Exon 11+ 17/18

ROMVIMZA®

(Vimseltinib)
c
CSF1R inhibitor
  • Symptomatic TGCT, not amenable to surgery ᵈ

Tirabrutinib
e

BTK Inhibitor
  • PCNSL, ≥2L
  • PCNSL, 1L, ≥2L (with high dose methotrexate-based regimens)

Sapablursen
f

Antisense Oligonucleotide Targeting TMPRSS6
  • Polycythemia Vera, phlebotomy-dependent

ONO-4578
e

Prostaglandin receptor (EP4) antagonist
  • Gastric Cancer, 1L (with nivolumab and chemotherapy)
  • Colorectal Cancer, 1L (with nivolumab, chemotherapy and bevacizumab)

Inlexisertib

ULK inhibitor
  • Advanced Malignancies (with ripretinib)

DCC-3009

Pan-KIT inhibitor
  • Advanced GIST

DCC-2812

GCN2 Activator
  • Advanced or Metastatic Genitourinary Cancers

ONO-4685
e

PD-1 x CD3 bispecific antibody
  • T-Cell Lymphoma, 2L

Specialty Areas (Immunology & Inflammation, and Neurology)

Vimseltinib

CSF1R inhibitor
  • cGVHD after failure of prior systemic therapy

ONO-2808
e

S1P5 receptor agonist
  • Multiple System Atrophy

ONO-2020
e

Epigenetic regulator
  • Alzheimer’s Disease

Recruiting Clinical Trials:

 

Vimseltinib
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
Tirabrutinib
IGNITE: Study of Tirabrutinib vs Rituximab/​Temozolomide for Relapsed/​Refractory Primary Central Nervous System Lymphoma (PCNSL) (IGNITE) (NCT07104032)
Sapablursen
A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV) (INTREPID) (NCT07429266)
ONO-4578
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/​dMMR, PD-L1 Positive Advanced Colorectal Cancer (NCT06948448)
Inlexisertib
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies (NCT05957367)
DCC-3009
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) (NCT06630234)
DCC-2812
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers (NCT06966024)
ONO-4685
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma (NCT05079282)
  • Oncology
  • Disease/Condition: Relapsed/Refractory T-Cell Lymphoma

The safety and efficacy of the agents for the indications under investigation has not been established. There is no guarantee that the outcomes of these studies will result in approval by a Health Authority.